Hal Stern

Learn More
At the request of the Food and Drug Administration (FDA) and with its funding, the Panel on the Handling of Missing Data in Clinical Trials was created by the National Research Council's Committee on National Statistics. This panel recently published a report(1) with recommendations that will be of use not only to the FDA but also to the entire clinical(More)
This paper extends an approach for estimating the ancestry probability, the probability that an inbred line is an ancestor of a given hybrid, to account for genotyping errors. The effect of such errors on ancestry probability estimates is evaluated through simulation. The simulation study shows that if misclassification is ignored, then ancestry(More)
Rob Kass presents a fascinating vision of a " post "-Bayes/frequentist-controversy world in which practical utility of statistical models is the guiding principle for statistical inference. I agree with Kass on many points. In particular, Kass is correct (in my opinion) when he notes that much modern statistical work develops statistical models (the(More)
  • 1